RxDoctor Payments Data

Jeffrey Schultze, MD

Internal Medicine · Charleston, SCNPI 1881660918

Payments from drug & device makers

$6,896in general payments, 2019–2025

Across 354 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$887
  • AbbVie$548
  • Lilly USA, LLC$493
  • Novo Nordisk$383
  • Pfizer$369
  • GSK$355
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$6,66397%
  • Gifts$2333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,896 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$152,006
Medicare patients
202
Services billed
3,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$60,043
JanuviaSitagliptin Phosphate33$45,718
EliquisApixaban41$43,268
FarxigaDapagliflozin Propanediol22$19,708
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,042
BelbucaBuprenorphine Hcl12$11,948
JardianceEmpagliflozin13$9,745
Xtampza ErOxycodone Myristate13$8,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$4,478
Testosterone11$3,599
Rosuvastatin Calcium161$2,951
Atorvastatin Calcium279$2,860
Albuterol Sulfate HfaAlbuterol Sulfate67$2,839
Diclofenac Sodium27$2,521
Omeprazole158$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$493$60,04356 claims
MerckJanuvia$15$45,71833 claims
PfizerEliquis$369$43,26841 claims
AstraZenecaFarxiga$887$19,70822 claims
GSKTrelegy Ellipta$355$16,04217 claims
Boehringer IngelheimJardiance$99$9,74513 claims
Almatica Pharma LLCSertraline Hcl$28$1,08976 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →